Drug Trial Radar · NCT05699759
Safety and Effect of Intravitreal Injection of a Derivative of Nucleoside Reverse Transcriptase Inhibitor in Subjects with Diabetic Macular Edema
Last checked: Nov 19, 2026Latest source record: Nov 1, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1
Actual
Start
Jan 4, 2024
Primary completion
Jun 20, 2024
Study completion Jun 20, 2024
Sponsor
- Lead sponsor
- Michelle Abou-JaoudeAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Inflammasome Therapeutics
- First posted
- Jan 26, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is designed to assess the safety and initial evidence of efficacy of the novel compound SOM-401 (K8), a derivative of a nucleoside reverse transcriptase inhibitor, in subjects with untreated, clinically significant, diabetic macular edema (DME).
Conditions
- Diabetic Macular Edema
Interventions
K8Drug
Subjects will have the treatment administered intravitreally (one eye only) using an injector system on a 24-gauge needle to deliver a cylindrical, 3 mm long, drug eluting pellet containing 300 µg of K8. Participants will be followed for 168 days (24 weeks).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Mean change in central subfield thicknessTime frame: At week 4 (change as measured from baseline)
- Mean change in best-corrected visual acuity (BCVA)Time frame: At week 4 (change as measured from baseline)
- Adverse EventsTime frame: Within the study period (of 24 weeks)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
University of Kentucky
Lexington, Kentucky
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.